Ondine Biomedical Inc - Common Share

NEW
LSE:OBI (Canada)   Common Share
£ 0.08 (0%) Dec 12
At Loss
P/B:
15.50
Market Cap:
£ 33.03M ($ 41.81M)
Enterprise V:
£ 32.55M ($ 41.21M)
Volume:
14.07K
Avg Vol (2M):
578.04K
Warning! GuruFocus detected 4 Severe warning signs with OBI. Try a 7-Day Free Trial to check it out.
Trade In:
Volume:
14.07K
Market Cap £:
33.03M
Market Cap $:
41.81M
At Loss
Avg Vol (2M):
578.04K
Enterprise Value £:
32.55M
Enterprise Value $:
41.21M
PB Ratio:
15.50
Website Sources Stock PDF
Dataset
Financial Download GuruFocus Premium Icon Manual of Stocksâ„¢

Business Description

Ondine Biomedical Inc
NAICS : 541714 SIC : 3741
ISIN : CA68234M2058
https://www.ondinebio.com
1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6

Share Class Description:

LSE:OBI: Common Share
Compare
Compare
AQSE:INCLSE:ARECLSE:ONCLSE:HEMOLSE:SARLSE:SBTXLSE:OPTILSE:IXILSE:POLBLSE:SNGVRTXASX:CSLREGNXKRX:207940XBRU:ARGXXBRU:UCBALNYBNTXXKRX:068270BGNE
Traded in other countries / regions
OBI.UKOBIMF.USAVF5.Germany
IPO Date
2021-12-06
Description
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 3.48
Equity-to-Asset 0.01
Debt-to-Equity 18.27
Debt-to-EBITDA -0.03
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -63.61
Distress
Grey
Safe
Beneish M-Score -2.22
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year Revenue Growth Rate -7.2
3-Year EBITDA Growth Rate 1.6
3-Year EPS without NRI Growth Rate 4.4
3-Year FCF Growth Rate -29.2
Future 3-5Y EPS without NRI Growth Rate Estimate 34.84
Future 3-5Y Total Revenue Growth Rate Estimate 125.96

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 39.96
9-Day RSI 42.1
14-Day RSI 46.46
3-1 Month Momentum % 25.49
6-1 Month Momentum % 6.67
12-1 Month Momentum % -11.11

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.8
Quick Ratio 0.48
Cash Ratio 0.3
Days Inventory 645.47
Days Sales Outstanding 48.97
Days Payable 647.39

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -5.2
Shareholder Yield % -9.83

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % 59.96
Operating Margin % -893.57
Net Margin % -873.24
FCF Margin % -768.91
ROE % -670.11
ROA % -246.17
ROIC % -491.02
3-Year ROIIC % -2.64
ROC (Joel Greenblatt) % -1465.07
ROCE % -594.89

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 19.38
PB Ratio 15.5
Price-to-Tangible-Book 7.75
EV-to-EBIT -3.94
EV-to-Forward-EBIT -3.7
EV-to-EBITDA -4.1
EV-to-Forward-EBITDA -1.98
EV-to-Revenue 34.31
EV-to-Forward-Revenue 11.82
EV-to-FCF -4.46
Earnings Yield (Greenblatt) % -25.37
FCF Yield % -22.09

Financials (Next Earnings Date:2025-06-06 Est.)

LSE:OBI's 30-Y Financials
AAPL
Income Statement Breakdown FY
No Enough Data
AAPL
Balance Sheet Breakdown
No Enough Data
AAPL
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Ondine Biomedical Inc Executives

Details

GF Value

LSE:OBI

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil £) 0.949
EPS (TTM) (£) -0.035
Beta -0.03
3-Year Sharpe Ratio -
3-Year Sortino Ratio -
Volatility % 82.37
14-Day RSI 46.46
14-Day ATR (£) 0.004031
20-Day SMA (£) 0.079688
12-1 Month Momentum % -11.11
52-Week Range (£) 0.05 - 0.114
Shares Outstanding (Mil) 426.23

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Ondine Biomedical Inc Filings

Filing Date Document Date Form
No Filing Data

Ondine Biomedical Inc Stock Events

Financials Calendars
Event Date Price (£)
No Event Data

Ondine Biomedical Inc Frequently Asked Questions

What is Ondine Biomedical Inc(LSE:OBI)'s stock price today?
The current price of LSE:OBI is £0.08. The 52 week high of LSE:OBI is £0.11 and 52 week low is £0.05.
When is next earnings date of Ondine Biomedical Inc(LSE:OBI)?
The next earnings date of Ondine Biomedical Inc(LSE:OBI) is 2025-06-06 Est..
Does Ondine Biomedical Inc(LSE:OBI) pay dividends? If so, how much?
Ondine Biomedical Inc(LSE:OBI) does not pay dividend.

Press Release

Subject Date
No Press Release
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.